RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Abhijit Date to Nanoparticles

This is a "connection" page, showing publications Abhijit Date has written about Nanoparticles.
Connection Strength

4.290
  1. Date AA, Kates M, Yoshida T, Babu T, Afzal U, Kanvinde P, Baras A, Anders N, He P, Rudek M, Hanes J, Bivalacqua TJ, Ensign LM. Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer. Drug Deliv Transl Res. 2021 10; 11(5):2085-2095.
    View in: PubMed
    Score: 0.544
  2. Kulkarni M, Goge N, Date AA. Development of Nanoemulsion Preconcentrate of Capsanthin with Improved Chemical Stability. Assay Drug Dev Technol. 2020 01; 18(1):34-44.
    View in: PubMed
    Score: 0.501
  3. Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, Narayan J, Zierden H, Betageri K, Musmanno O, Wiegand H, Huang X, Gumber S, Hanes J, Ensign LM. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018 12; 185:97-105.
    View in: PubMed
    Score: 0.468
  4. Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J Control Release. 2016 10 28; 240:504-526.
    View in: PubMed
    Score: 0.400
  5. Date AA, Shibata A, Bruck P, Destache CJ. Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates. Biomed Chromatogr. 2015 May; 29(5):709-15.
    View in: PubMed
    Score: 0.357
  6. Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, Destache CJ. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res. 2012 Dec; 96(3):430-6.
    View in: PubMed
    Score: 0.310
  7. Date AA, Vador N, Jagtap A, Nagarsenker MS. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. Nanotechnology. 2011 Jul 08; 22(27):275102.
    View in: PubMed
    Score: 0.282
  8. Date AA, Nagarsenker MS, Patere S, Dhawan V, Gude RP, Hassan PA, Aswal V, Steiniger F, Thamm J, Fahr A. Lecithin-based novel cationic nanocarriers (Leciplex) II: improving therapeutic efficacy of quercetin on oral administration. Mol Pharm. 2011 Jun 06; 8(3):716-26.
    View in: PubMed
    Score: 0.280
  9. Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine (Lond). 2010 Dec; 5(10):1595-616.
    View in: PubMed
    Score: 0.273
  10. Date AA, Nagarsenker MS. Parenteral microemulsions: an overview. Int J Pharm. 2008 May 01; 355(1-2):19-30.
    View in: PubMed
    Score: 0.224
  11. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 2007 Jul 10; 59(6):505-21.
    View in: PubMed
    Score: 0.213
  12. Sutar Y, Nabeela S, Singh S, Alqarihi A, Solis N, Ghebremariam T, Filler S, Ibrahim AS, Date A, Uppuluri P. Niclosamide-loaded nanoparticles disrupt Candida biofilms and protect mice from mucosal candidiasis. PLoS Biol. 2022 08; 20(8):e3001762.
    View in: PubMed
    Score: 0.154
  13. Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ. Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2017 Nov 01; 23(21):6592-6601.
    View in: PubMed
    Score: 0.109
  14. Shibata A, McMullen E, Pham A, Belshan M, Sanford B, Zhou Y, Goede M, Date AA, Date AA, Destache CJ. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses. 2013 May; 29(5):746-54.
    View in: PubMed
    Score: 0.079
  15. Kim YC, Shin MD, Hackett SF, Hsueh HT, Lima E Silva R, Date A, Han H, Kim BJ, Xiao A, Kim Y, Ogunnaike L, Anders NM, Hemingway A, He P, Jun AS, McDonnell PJ, Eberhart C, Pitha I, Zack DJ, Campochiaro PA, Hanes J, Ensign LM. Gelling hypotonic polymer solution for extended topical drug delivery to the eye. Nat Biomed Eng. 2020 11; 4(11):1053-1062.
    View in: PubMed
    Score: 0.034
  16. Destache CJ, Mandal S, Yuan Z, Kang G, Date AA, Lu W, Shibata A, Pham R, Bruck P, Rezich M, Zhou Y, Vivekanandan R, Fletcher CV, Li Q. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model. Antimicrob Agents Chemother. 2016 06; 60(6):3633-9.
    View in: PubMed
    Score: 0.025
  17. Kovarova M, Council OD, Date AA, Long JM, Nochi T, Nochii T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog. 2015 Aug; 11(8):e1005075.
    View in: PubMed
    Score: 0.024
  18. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007 Dec 10; 345(1-2):163-71.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support